Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.77T
24h Vol:
$10.38B
Dominance:
MSFT:4.81%
Stocklytics Platform
Asset logo  CRSP
CRISPR Therapeutics AG
CRSP
62 / 100
$53.39arrow_drop_down2.63%-$1.44

Performance History

Chart placeholder
Key Stats
Open$56.80
Prev. Close$56.80
EPS-2.7
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$4.70B
PE Ratio-
LOWHIGH
Day Range54.32
56.80
52 Week Range37.55
91.10
Ratios
P/B Ratio2.74
Revenue$370.00M
Operating M. %-27,894.25%
Earnings$0.00
Earnings Growth %76.37%
EBITDA Margin %-75.41%
ROE %-11.02%
EPS-2.7

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$808.45
24H (%)arrow_drop_up0.69%
24H ($)$5.54
MARKET CAP$744.33B
PRICE$516.83
24H (%)arrow_drop_down0.86%
24H ($)-$4.51
MARKET CAP$476.05B
PRICE$149.70
24H (%)arrow_drop_down2.47%
24H ($)-$3.80
MARKET CAP$364.05B
PRICE$131.09
24H (%)0.00%
24H ($)-$0.01
MARKET CAP$332.27B

About CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Samarth Kulkarni Ph.D.
Headquarters
Zug
Employees
458
Exchange
NASDAQ
add CRISPR Therapeutics AG to watchlist

Keep an eye on CRISPR Therapeutics AG

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is CRISPR Therapeutics AG's (CRSP) price per share?

The current price per share for CRISPR Therapeutics AG (CRSP) is $55.73. The stock has seen a price change of -$1.07 recently, indicating a -1.88% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for CRISPR Therapeutics AG (CRSP)?

For CRISPR Therapeutics AG (CRSP), the 52-week high is $91.1, which is 63.47% from the current price. The 52-week low is $37.55, the current price is 48.42% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is CRISPR Therapeutics AG (CRSP) a growth stock?

CRISPR Therapeutics AG (CRSP) has shown an average price growth of 0.41% over the past three years. It has received a score of 27 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying CRISPR Therapeutics AG as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is CRISPR Therapeutics AG (CRSP) stock price performance year to date (YTD)?

As of the latest data, CRISPR Therapeutics AG (CRSP) has a year-to-date price change of -15.64%. Over the past month, the stock has experienced a price change of 3.38%. Over the last three months, the change has been -35.24%. Over the past six months, the figure is -22.18%. Looking at a longer horizon, the five-year price change stands at 51.77%.

help
Is CRISPR Therapeutics AG (CRSP) a profitable company?

CRISPR Therapeutics AG (CRSP) has a net income of -$153.61M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 64.8% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -27.89K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $370M, although specific revenue growth data is currently not available. The gross profit is $239.75M. Operating income is noted at -$222.54M. Furthermore, the EBITDA is -$279.02M.

help
What is the market capitalization of CRISPR Therapeutics AG (CRSP)?

CRISPR Therapeutics AG (CRSP) has a market capitalization of $4.7B. The average daily trading volume is 1.42M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level